Abstract :

Benign prostatic hyperplasia (BPH) is a common non-malignant enlargement of the prostate gland in ageing males and is associated with hormonal imbalances, inflammation and biochemical alterations. It could be detected biochemically through prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) assay. Plant-based interventions have gained increasing attention due to their affordability, safety, and rich phytochemical composition. Phaseolus vulgaris (black bean) is a legume containing phenolics, flavonoids, and bioactive peptides with antioxidant and anti-inflammatory properties, but its effect on prostate biomarkers has not been clearly established. This study investigated the effect of cooked black bean juice on PSA and PAP levels in testosterone-propionate induced BPH male albino rats. Twenty-four adult rats (150–280 g) were divided into four groups after induction of BPH by subcutaneous testosterone propionate. Animals were treated with graded doses of cooked P. vulgaris juice (low, medium, and high), while the control group received no extract. Serum PSA (ng/mL) and PAP (IU/L) were analyzed before and after treatment. Results showed that induction of BPH significantly elevated PSA and PAP. Administration of cooked black bean juice produced significant reductions (p < 0.05) in both biomarkers across all treated groups. PAP decreased from 11.55 ± 0.76 to 7.62 ± 0.93 in the high-dose group, 11.42 ± 0.98 to 7.32 ± 0.66 in the medium-dose group, and 10.73 ± 1.49 to 7.15 ± 0.68 in the low-dose group. PSA declined correspondingly from 3.12 ± 0.46 to 1.79 ± 0.58, 3.04 ± 0.54 to 1.77 ± 0.69, and 2.94 ± 0.40 to 1.22 ± 0.48 respectively. A strong positive correlation existed between PSA and PAP (r = 0.97, p = 0.000), indicating that reductions in these markers were closely related. The study concludes that cooked P. vulgaris juice exerts beneficial effects on prostate biochemical indices in BPH and may serve as a natural therapeutic adjunct in prostate health management

---

Keywords :

Acid phosphatase, Benign prostatic hyperplasia, Phaseolus vulgaris, Prostate specific antigen, Rats., Testosterone

---

References :

1. Anderson, J.B. and Loeb, S. (2022) ‘Dietary phytochemicals and benign prostatic hyperplasia: mechanisms and clinical implications’, Prostate Cancer and Prostatic Diseases, 25(3), pp. 435–444
2. Bostwick, D.G. (2020) ‘Prostatic acid phosphatase: its role in prostate disease’, Urologic Clinics of North America, 47(2), pp. 187–195
3. Carson, C. and Rittmaster, R. (2020) ‘The role of dihydrotestosterone in benign prostatic hyperplasia’, Urology, 85(1), pp. 17–24
4. Diaz-Balteiro, L., Martinez-Vergara, A. and Sanchez-Chino, X. (2023) ‘Bioactive compounds of black beans (Phaseolus vulgaris) and their health benefits’, Journal of Food Biochemistry, 47(1), e14123
5. Fowler, C.J. and Kirby, R.S. (2020) ‘Benign prostatic hyperplasia: epidemiology and clinical management’, BMJ, 371, m3811
6. Hayes, J.H. and Barry, M.J. (2019) ‘Screening for prostate cancer with the prostate-specific antigen test’, New England Journal of Medicine, 344(18), pp. 1351–1357
7. Hernandez, J., Thompson, I.M. and Klein, E.A. (2021) ‘Biochemical markers in benign and malignant prostate diseases’, Clinical Chemistry, 67(4), pp. 560–569
8. Hernandez-Martinez, R., Diaz-Balteiro, L. and Sanchez-Chino, X. (2021) ‘Legume-derived bioactive compounds and enzyme inhibition in androgen-related disorders’, Journal of Ethnopharmacology, 268, 113605
9. Hoffmann, R., Schulze, M. and Jonas, U. (2022) ‘Physiology and secretory function of the prostate gland’, Andrology, 10(2), pp. 345–354
10. Kim, E.H., Brockman, J.A. and Andriole, G.L. (2021) ‘Dietary and plant-based therapies for benign prostatic hyperplasia’, Current Opinion in Urology, 31(1), pp. 23–29
11. Lilja, H., Ulmert, D. and Vickers, A.J. (2022) ‘Prostate-specific antigen and prostate cancer: prediction, detection and monitoring’, Nature Reviews Cancer, 22(6), pp. 367–382
12. Madersbacher, S., Sampson, N. and Culig, Z. (2019) ‘Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement’, European Urology, 75(5), pp. 712–719
13. Martinez-Vergara, A., Diaz-Balteiro, L. and Sanchez-Chino, X. (2022) ‘Protein hydrolysates and phenolic fractions from legumes: biological activity and therapeutic relevance’, Food Research International, 156, 111153
14. OECD (2020) Guidance document on the recognition, assessment and use of clinical signs as humane endpoints for experimental animals. Paris: Organisation for Economic Co-operation and Development
15. Roehrborn, C.G. (2021) ‘Benign prostatic hyperplasia: an overview’, Reviews in Urology, 23(2), pp. 79–86
16. Sánchez-Chino, X., Jiménez-Martínez, C., Dávila-Ortiz, G. and Álvarez-González, I. (2020) ‘Nutritional and functional properties of Phaseolus vulgaris’, Food Science and Nutrition, 8(2), pp. 579–589
17. Timothy, O., Adebayo, A.O. and Olusegun, A.O. (2022) ‘Testosterone-induced benign prostatic hyperplasia model in rats: biochemical and histological evaluation’, Journal of Experimental And Clinical Anatomy, 21(1), pp. 45–52